[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638139":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":164,"collaborators":24,"id":166,"slug":167,"hasResults":168,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":24,"eligibilityCriteria":172,"healthyVolunteers":168,"sex":173,"minAge":174,"maxAge":24,"enrollmentInfo":175,"targetDuration":24,"studyType":178,"phases":179,"briefSummary":181,"conditions":182,"keywords":24,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},{"fullName":5,"class":6},"Relay Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: RLY-8161 for participants with advanced NRAS-mutant solid tumors","EXPERIMENTAL","Multiple doses of RLY-8161 for oral administration",[13],"Drug: RLY-8161",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2: RLY-8161 for participants with advanced NRAS-mutant solid tumors","Oral doses of RLY-8161 as determined during Part 1 Dose Escalation",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","RLY-8161","RLY-8161 is an NRAS-selective inhibitor",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Relay Therapeutics, Inc","CONTACT","617-322-0731","ClinicalTrials@relaytx.com",[32,51,65,80,95,106,120,134,149],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"University of California, Los Angeles","RECRUITING","Los Angeles","California","90095","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-118.24368,34.05223,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":49,"phoneExt":24,"email":50},"Bartosz Chmielowski, MD","310-794-4655","bchmielowski@mednet.ucla.edu",{"facility":52,"status":34,"city":53,"state":36,"zip":54,"country":38,"countryCode":39,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"University of California, San Francisco","San Francisco","94143",{"type":41,"coordinates":56},[57,58],-122.41942,37.77493,{"lat":58,"lon":57},[61],{"name":62,"role":28,"phone":63,"phoneExt":24,"email":64},"Sonia C Martinez","415-714-4484","Sonia.ContrerasMartinez@ucsf.edu",{"facility":66,"status":34,"city":67,"state":68,"zip":69,"country":38,"countryCode":39,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"University of Colorado Hospital","Aurora","Colorado","80045",{"type":41,"coordinates":71},[72,73],-104.83192,39.72943,{"lat":73,"lon":72},[76],{"name":77,"role":28,"phone":78,"phoneExt":24,"email":79},"Meagan Brander","303-724-8869","MAEGAN.BRANDER@CUANSCHUTZ.EDU",{"facility":81,"status":34,"city":82,"state":83,"zip":84,"country":38,"countryCode":39,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":41,"coordinates":86},[87,88],-71.05977,42.35843,{"lat":88,"lon":87},[91],{"name":92,"role":28,"phone":93,"phoneExt":24,"email":94},"Ryan Sullivan, MD","617-243-5480","RSULLIVAN7@mgh.harvard.edu",{"facility":96,"status":34,"city":82,"state":83,"zip":97,"country":38,"countryCode":39,"cosmosGeoPoint":98,"geoPoint":100,"contacts":101},"Dana Farber Cancer Institute","02215",{"type":41,"coordinates":99},[87,88],{"lat":88,"lon":87},[102],{"name":103,"role":28,"phone":104,"phoneExt":24,"email":105},"Linnea Drew","617-632-6704","Linneam_drew@dfci.harvard.edu",{"facility":107,"status":34,"city":108,"state":109,"zip":110,"country":38,"countryCode":39,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"START Midwest, LLC","Grand Rapids","Michigan","49546",{"type":41,"coordinates":112},[113,114],-85.66809,42.96336,{"lat":114,"lon":113},[117],{"name":24,"role":28,"phone":118,"phoneExt":24,"email":119},"616-954-5554","hopeteam@startresearch.com",{"facility":121,"status":34,"city":122,"state":122,"zip":123,"country":38,"countryCode":39,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":41,"coordinates":125},[126,127],-74.00597,40.71427,{"lat":127,"lon":126},[130],{"name":131,"role":28,"phone":132,"phoneExt":24,"email":133},"Monica Chen, MD","646-888-5108","ChenM9@mskcc.org",{"facility":135,"status":34,"city":136,"state":137,"zip":138,"country":38,"countryCode":39,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Sarah Cannon Research Institute Oncology Partners","Nashville","Tennessee","37203",{"type":41,"coordinates":140},[141,142],-86.78444,36.16589,{"lat":142,"lon":141},[145],{"name":146,"role":28,"phone":147,"phoneExt":24,"email":148},"ASKSarah","877-MY-1-SCRI (691-7274)","ASKSARAH@scresearch.net",{"facility":150,"status":34,"city":151,"state":152,"zip":153,"country":38,"countryCode":39,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"NEXT Virginia","Fairfax","Virginia","22031",{"type":41,"coordinates":155},[156,157],-77.30637,38.84622,{"lat":157,"lon":156},[160],{"name":161,"role":28,"phone":162,"phoneExt":24,"email":163},"Paolo Umayam","703-783-4546","pumayam@nextoncology.com",{"type":165,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100638139","phase-1-a-first-in-human-study-of-rly-8161-in-advanced-nras-mutant-solid-tumors-100638139",false,"NCT07584226","A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors","A First-in-human Study of RLY-8161 for Treatment of Advanced NRAS-Mutant Melanoma and Other Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Histologically confirmed diagnosis of unresectable Stage III or IV melanoma or other solid tumor.\n* Disease is refractory to standard therapy (including targeted therapy), participant is intolerant of standard therapy, or participant has declined standard therapy.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* One or more documented primary oncogenic NRAS mutation(s).\n\nExclusion Criteria:\n\n* Known activating KRAS, HRAS, or BRAF mutation or known alterations in other driver oncogenes.\n* Prior treatment with ERK, MEK, RAF, or RAS targeting agents or any agent whose mechanism of action is to inhibit the RAS-MAPK pathway.\n* For participants with melanoma: lactate dehydrogenase (LDH) \\>2×ULN.\n* Central nervous system (CNS) metastases that are associated with progressive neurologic symptoms or require ongoing corticosteroids to control the CNS disease.","ALL","18 Years",{"count":176,"type":177},35,"ESTIMATED","INTERVENTIONAL",[180],"PHASE1","This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.",[183,184,185,186,187,188,189,190,191,192,193],"Advanced NRAS-Mutant Melanoma","Advanced NRAS-Mutant Solid Tumors","NRAS Mutation","NRAS G12D","NRAS G13R","NRAS G13D","NRAS G12V","NRAS Q61R","NRAS Q61K","NRAS Q61L","NRAS Q61H","2026-06-30",{"date":196,"type":197},"2026-07-02","ACTUAL",{"date":199,"type":197},"2026-03-09",{"date":201,"type":177},"2029-12-31",{"name":5,"class":6},9]